相关实验视频
Updated: Jul 12, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
糖尿病患病率上升:来自丹麦药物流行病学数据库的证据
Henrik Støvring1, Morten Andersen, Henning Beck-Nielsen
1Research Unit of General Practice, University of Southern Denmark, DK-5000, Odense, Denmark. hstovring@health.sdu.dk <hstovring@health.sdu.dk>
Lancet (London, England)
|August 23, 2003
概括
全球糖尿病患病率正在上升. 然而,丹麦的一项研究发现,尽管病例数量增加,但治疗糖尿病患者的死亡率在1993年至今期间下降.
科学领域:
- 流行病学 流行病学
- 公共卫生 公共卫生
- 内分泌学 在内分泌学.
背景情况:
- 全球糖尿病患病率正在增加,需要流行病学研究来了解趋势.
- 药物治疗糖尿病需要仔细监测患病率,发病率和死亡率.
- 基于社区的研究对于准确的健康趋势分析至关重要.
研究的目的:
- 在一个定义的社区进行药物治疗糖尿病的流行病学分析.
- 为了估计在丹麦的Fyn县糖尿病的流行,发病率和死亡率.
- 分析随着时间的推移糖尿病的趋势,并确定影响这些趋势的因素.
主要方法:
- 丹麦费恩县47万人口的流行病学分析.
- 在研究期间包括所有药物治疗糖尿病患者.
- 对流行率,发病率和死亡率数据的统计分析.
主要成果:
- 糖尿病患病率在女性 (OR 1.026) 和男性 (OR 1.041) 均显著增加.
- 在接受治疗的糖尿病患者中,死亡率在女性 (RR 0.976) 和男性 (RR 0.966) 均有下降.
- 在研究期间,没有发现糖尿病发病率的明确趋势.
结论:
- 糖尿病患病率上升并不一定与治疗个体的死亡率增加有关.
- 治疗糖尿病患者的死亡率下降应该在未来对生活方式因素的研究中考虑.
- 需要进一步调查,以了解生活方式,糖尿病患病率上升和死亡率趋势之间的复杂关系.
相关概念视频
Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetic Nephropathy
Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
